Drug recall · February 17, 2021
Glycopyrrolate Injection recall
Why: Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)
- Lots / codes
Lot: M2013645 Exp. Aug. 2022
- Quantity
- 502 cartons
- Company
- Accord Healthcare, Inc., Durham, NC
- Distribution
- Nationwide
- Initiated
- January 28, 2021 · Voluntary: Firm initiated
- Classified
- February 8, 2021
- Reported
- February 17, 2021
- Ended
- February 8, 2022
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.